Healthcare
Esperion Therapeutics, Inc.(ESPR)
Live Price
Offline$3.15
-0.63% today
1Y Change
+211.88%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $650.00M
- Revenue Growth
- +21.3%
- EPS Growth
- +60.7%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Esperion Therapeutics, Inc. (ESPR) is a Healthcare stock with a market cap of $650.00M and listed on NASDAQ. The stock last traded around $3.15 and up 211.9% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +21.3%, EPS growth of +60.7%, a dividend yield of 0.0%. What stands out right now is revenue +21.3%, EPS +60.7%, free cash flow +46.2% with operating margin 15.0% and ROIC 23.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ESPR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+21.3% vs +7.6% peer median
Operating Margin
Below sector median
+15.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +21.3% and EPS at +60.7%, with operating margin around 15.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.4% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +1.0% | +0.3% | +0.6% |
2026 Mar 10, 2026 | -4.3% | -4.1% | +0.4% | -13.7% |
2025 Nov 6, 2025 | -77.8% | +6.4% | +18.4% | +49.2% |
Benchmark Edge
ESPR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ESPR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ESPR Max Drawdown
-53.19%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ESPR and SPY.
Company Overview
Esperion Therapeutics, Inc.
NASDAQ Global Market
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
- Leadership
- Sheldon L. Koenig
- IPO Date
- Jun 26, 2013
- Employees
- 304
- Street Address
- 3891 Ranchero Drive
- Mailing
- Ann Arbor, MI, 48108
- Region
- Ann Arbor, MI, US
- Reporting Currency
- USD
- Investor Line
- 734 887 3903
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 16.4
- Price/Sales
- 1.6
- Price/Book
- โ
Growth
- Revenue
- +21.3%
- EPS
- +60.7%
- Free Cash Flow
- +46.2%
Profitability
- Gross Margin
- 64.4%
- Operating Margin
- 15.0%
- Net Margin
- -5.6%
- ROE
- 5.6%
- ROIC
- 23.7%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.56
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.